Diroximel fumarate and dimethyl fumarate demonstrate early clinical and radiological efficacy in relapsing-remitting multiple sclerosis (1337)

Objective: null To evaluate clinical and radiological efficacy in relapsing-remitting multiple sclerosis (RRMS) patients who received diroximel fumarate (DRF) or dimethyl fumarate (DMF) in EVOLVE-MS-2 and continued DRF in EVOLVE-MS-1. null Background: null DRF is an investigational, oral fumarate for relapsing forms of MS. DMF is an approved treatment option for relapsing forms of MS. DRF and DMF produce bioequivalent exposure of the active...